Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression.

A co-delivery system that can transport cancer related microRNAs and chemotherapeutics to their distinct targets in the tumors is an attractive strategy to eliminate tumor relapse in lung cancer therapy. In this study, we developed a dual-drug delivery system for an endogenous microRNA (miR-34a) and paclitaxel (PTX) for synergistic cancer therapy. PTX (a meiotic inhibitor) and miR-34a were loaded into cationic solid lipid nanoparticles (miSLNs-34a/PTX) which were used to treat murine B16F10-CD44(+) melanoma metastasized to the lungs of mice. This nanoparticle system demonstrated good protection for miR-34a and PTX from degradation in the serum, and had an average size of approximately 220 nm by photon correlation spectroscopy (PCS). In vitro, the parallel activity of PTX and miR-34a show synergistic anticancer efficacy. In vivo, miSLNs-34a/PTX showed passive targetability to the tumor-bearing lung tissues, and was demonstrated to be much more potent in inhibition of B16F10-bearing tumor growth and elimination of cancer cell populations in the lung than single drug-loaded solid lipid nanoparticles. It has been shown that such co-delivery of miR-34a and PTX is promising for enhanced cancer therapy to reduce tumor relapse.

[1]  T. Deguchi,et al.  MiR‐34a attenuates paclitaxel‐resistance of hormone‐refractory prostate cancer PC3 cells through direct and indirect mechanisms , 2010, The Prostate.

[2]  M. S. Singh,et al.  Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. , 2013, International journal of pharmaceutics.

[3]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[4]  M. Yamakuchi,et al.  miR-34a repression of SIRT1 regulates apoptosis , 2008, Proceedings of the National Academy of Sciences.

[5]  Jijin Gu,et al.  Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation. , 2010, International journal of pharmaceutics.

[6]  P. Wakeley,et al.  Synthesis , 2013, The Role of Animals in Emerging Viral Diseases.

[7]  B. Yin,et al.  Tumor suppressor microRNA-34a inhibits cell proliferation by targeting Notch1 in renal cell carcinoma , 2014, Oncology letters.

[8]  M. Wani,et al.  Camptothecin and taxol: from discovery to clinic. , 1996, Journal of ethnopharmacology.

[9]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[10]  Tonglei Li,et al.  Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Michael F. Clarke,et al.  Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells , 2009, Cell.

[12]  D. Brown,et al.  The promise of microRNA replacement therapy. , 2010, Cancer research.

[13]  R. Shiekhattar,et al.  MicroRNA biogenesis and cancer. , 2005, Cancer research.

[14]  P. Caliceti,et al.  Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  Kohei Tahara,et al.  Chitosan-modified poly(d,l-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects , 2009, European Journal of Pharmaceutics and Biopharmaceutics.

[16]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[17]  I. Weissman,et al.  Frequency of cells expressing CD44, a Head and Neck cancer stem cell marker: Correlation with tumor aggressiveness , 2012, Head & neck.

[18]  X J Li,et al.  MicroRNA-34a: a potential therapeutic target in human cancer , 2014, Cell Death and Disease.

[19]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[20]  Tao Gong,et al.  Systemic delivery of microRNA-34a for cancer stem cell therapy. , 2013, Angewandte Chemie.

[21]  Kai-Fai Lee,et al.  MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. , 2010, Carcinogenesis.

[22]  Wei Zhang,et al.  The potential of Pluronic polymeric micelles encapsulated with paclitaxel for the treatment of melanoma using subcutaneous and pulmonary metastatic mice models. , 2011, Biomaterials.

[23]  B. Liu,et al.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Giuseppe Basso,et al.  MiR-34a Targeting of Notch Ligand Delta-Like 1 Impairs CD15+/CD133+ Tumor-Propagating Cells and Supports Neural Differentiation in Medulloblastoma , 2011, PloS one.

[25]  Yaping Li,et al.  Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. , 2012, Biomaterials.

[26]  M. Ivan,et al.  microRNA: emerging therapeutic targets in acute ischemic diseases. , 2010, Pharmacology & therapeutics.

[27]  B. Zhang,et al.  LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. , 2013, Biomaterials.

[28]  R. Vento,et al.  SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib , 2007, Apoptosis.

[29]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[30]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[31]  Yunqing Li,et al.  MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. , 2009, Cancer research.

[32]  Xiling Shen,et al.  A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. , 2013, Cell stem cell.